A poster, titled ‘Neuroprotection in CNS demyelinating disease by SIRT1 activators, a potential oral therapy’ presented at the annual meeting of the american neurological association, showed that oral dosing of SRT501, a proprietary formulation of resveratrol, reduced the loss of retinal ganglion cells and preserved axonal function in a preclinical model of optic neuritis.
Peter Elliott, senior vice president of development at Sirtris, said: “This is the first time that an orally administered SIRT1 activator has demonstrated neuroprotection; these are encouraging data and further support the potential for SRT501 as a therapeutic for a range of neurodegenerative diseases of aging.”
Christoph Westphal, CEO of Sirtris, said: “These new findings add to a growing body of data that demonstrate that SIRT1 is an important therapeutic target for a broad range of diseases of aging, including metabolic, mitochondrial and neurological disorders.”